Form 4: Corvus Pharmaceuticals Director Peter A. Thompson Reports Acquisition of Stock Options

Director Peter A. Thompson reports the acquisition of 15,000 stock options in Corvus Pharmaceuticals.

Summary

• Peter A. Thompson, a director of Corvus Pharmaceuticals, filed a Form 4 disclosing changes in beneficial ownership.
• The report indicates that Thompson acquired 15,000 stock options on June 13, 2024, exercisable at $2.12 per share, expiring on June 13, 2034.
• These options vest on the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting, assuming continuous service as a director.
• Thompson indirectly holds 6,943,654 shares of common stock through OrbiMed Private Investments V, LP.
• Thompson disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
• Thompson is obligated to transfer any securities issued under the stock options, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OPI V.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports a transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction could have a minor impact on shareholders' perception of the company, depending on how they interpret the director's stock option acquisition.

Key Dates